Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
Novartis delivers strong financial performance in second quarter 20 July 2010
Novartis gains new indication for Diovan®* for the treatment of children and adolescents 03 May 2010
Novartis receives approval in the European Union for Menveo® 22 March 2010
Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression 25 January 2010
Novartis set to sustain its leading global position in oncology 10 December 2009
Novartis receives approval in the European Union for Onbrez® Breezhaler® 08 December 2009
Novartis receives regulatory approval in Germany for Celtura® 11 November 2009
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China 04 November 2009
Novartis unveils Lab of Future concept to top European students at Biotechnology Leadership Camp (BioCamp) 27 August 2009
Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer 10 August 2009
Novartis delivers strong operational performance in the first half of 2009 20 July 2009
Once-yearly Aclasta® approved in EU to treat osteoporosis 29 June 2009
Sandoz to acquire EBEWE Pharma specialty generics business 25 May 2009
Glivec® approved in EU as first post-surgery therapy 08 May 2009
Novartis expects strong operational performance in 2009 27 April 2009
Glivec® recommended for use in Europe as first post-surgery treatment for gastrointestinal stromal tumors (GIST) 22 March 2009
Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound 12 February 2009
Novartis increases dividend by 25% based on strong 2008 results 01 February 2009
Novartis launches Extavia®, the standard-of-care for relapsing forms of multiple sclerosis 26 January 2009
Four innovative Novartis medicines approved in Japan 21 January 2009